T-Mobile U.S. President: Strong Growth Will Bolster Sprint Merger Bid
*By Jeffrey Marcus*
T-Mobile announced Wednesday it had its best second quarter ever, booking earnings of $0.92 per share on $10.6 billion in total revenueーincluding a record $7.9 billion from services.
The wireless provider also added 1.6 million new customers, the 21st consecutive quarter in which subscribers grew by more than 1 million, the company said. T-Mobile also increased its target for branded postpaid customers to 3.6 million by the end of the year.
T-Mobile U.S. president and COO Mike Sievert said Wednesday in an interview with Cheddar that the company's growth would strengthen its hand in a proposed merger with rival Sprint. After several failed attempts which spanned a couple years, the companies announced an agreement to merge in April and have been working to earn government approval on the promise of increased competition from fewer, stronger rivals.
"The capacity of this network will create competition," Sievert said. "When we get this network built, it is going to have seven times the capacity of today's Sprint and T-Mobile combined. That's going to create a level of competition that AT&T, Verizon, and Comcast have never seen."
For more on this story, [click here](https://cheddar.com/videos/t-mobile-president-reacts-to-q2-earnings-and-merger-with-sprint).
Skift Editor-In-Chief Sarah Kopit discusses how summer travel plans remain uncertain for most as many international travelers are leery to travel abroad. Watch!
Seth Schachner, Managing Director at Strat Americas, on Hollywood's latest blockbusters utilizing content creation. Plus, the future of YouTube and TikTok.
Ashley Gold, Axios' Tech/Policy reporter, discusses what the future of Google and search engines will look like after the tech giant faces an antitrust trial.
Seth Goldstein, Equity Strategist at Morningstar, breaks down Tesla's earnings report, talks Musk's future with the company and how stocks have responded.
Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may change the healthcare industry.
